Država: Velika Britanija
Jezik: engleski
Izvor: MHRA (Medicines & Healthcare Products Regulatory Agency)
Magnesium sulfate heptahydrate
magnesium 2mmol/ml) solution for injection 5ml ampoules (Torbay Pharmaceuticals
B05XA05
Magnesium sulfate heptahydrate
500mg/1ml
Solution for injection
Intramuscular; Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 09050103; GTIN: 05060131262963
PATIENT INFORMATION LEAFLET MAGNESIUM SULFATE 50% W/V SOLUTION FOR INJECTION OR INFUSION • PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. • KEEP THIS LEAFLET IN A SAFE PLACE, YOU MAY WISH TO READ IT AGAIN. • IF YOU HAVE ANY QUESTIONS OR ARE NOT SURE ABOUT ANYTHING, ASK YOUR DOCTOR OR PHARMACIST. • IF ANY SIDE EFFECT GETS SERIOUS, OR IF YOU NOTICE ANY SIDE EFFECTS NOT LISTED IN THIS LEAFLET, PLEASE TELL YOUR DOCTOR OR PHARMACIST. IN THIS LEAFLET: 1. WHAT MAGNESIUM SULFATE SOLUTION FOR INJECTION OR INFUSION IS AND WHAT IT IS USED FOR 2. BEFORE YOU ARE GIVEN MAGNESIUM SULFATE SOLUTION FOR INJECTION OR INFUSION 3. HOW MAGNESIUM SULFATE SOLUTION FOR INJECTION OR INFUSION IS USED 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE MAGNESIUM SULFATE SOLUTION FOR INJECTION OR INFUSION 6. FURTHER INFORMATION 1. WHAT MAGNESIUM SULFATE SOLUTION FOR INJECTION OR INFUSION IS AND WHAT IT IS USED FOR Magnesium Sulfate, the active ingredient, plays a number of important roles in the body, and is involved in the regulation of the nervous and blood systems. This medicine is a solution for injection or infusion and is used for magnesium deficiency and prevention (and control) of seizures in patients with severe pre-eclampsia (high blood pressure associated with pregnancy) or eclampsia (convulsions as a result of pre-eclampsia). 2. BEFORE YOU ARE GIVEN MAGNESIUM SULFATE SOLUTION FOR INJECTION OR INFUSION THIS MEDICINE SHOULD NOT BE USED IF YOU: • Are allergic to magnesium or its salts • Have suffered from a disease of the brain associated with cirrhosis of the liver • Have had liver failure • Have had kidney failure • Have myasthenia gravis (a chronic progressive muscular weakness disease) • Suffer from heart disease Check with your doctor if you are concerned about any of the above. THIS MEDICINE SHOULD BE USED WITH CAUTION IN PATIENTS WHO ARE: • Suffering from impaired kidney function TAKING OTHER MEDICINES: Please tell your doctor if you are taking any other medication especially digitalis gly Pročitajte cijeli dokument
OBJECT 1 MAGNESIUM SULFATE 50%W/V SOLUTION FOR INJECTION OR INFUSION Summary of Product Characteristics Updated 14-Jul-2017 | Torbay & South Devon NHS Foundation Trust 1. Name of the medicinal product Magnesium Sulfate 50% w/v Solution for Injection or Infusion 2. Qualitative and quantitative composition Magnesium sulfate (heptahydrate) 50% w/v (approximately 2mmol Mg 2+ /mL). 3. Pharmaceutical form Solution for injection or infusion. 4. Clinical particulars 4.1 Therapeutic indications (a) Treatment of magnesium deficiency in hypomagnesaemia. (b) Prevention and control of generalised seizures in patients with severe pre-eclampsia or eclampsia. 4.2 Posology and method of administration Dosages should be adjusted according to the patient's needs and responses. Plasma levels should also be monitored during treatment. (a) TREATMENT OF MAGNESIUM DEFICIENCY IN HYPOMAGNESAEMIA: Up to 160mmol Mg 2+ by slow intravenous infusion (in glucose 5%) for up to 5 days, may be required to replace the deficit (allowing for urinary losses). Concentrations of no higher than 20% w/v should be given intravenously. Treatment may require repetition, for example during prolonged intravenous nutrition magnesium deficiency can occur, then parenteral doses of magnesium are of the order of 10 to 20mmol Mg 2+ daily (often about 12mmol Mg 2+ daily). Dosage for the elderly is similar to that for younger adults. Magnesium Sulfate 50% w/v Solution for Injection or Infusion should not be given to children. Appropriate reductions in dosage should be made for patients with renal impairment. (b) PREVENTION AND CONTROL OF SEIZURES ASSOCIATED WITH SEVERE PRE-ECLAMPSIA AND ECLAMPSIA: An initial intravenous (IV) loading dose of typically 4g (approximately 16mmol Mg 2+ ) given slowly over a period of 20 minutes or so, at a strength no higher than 20% w/v, is followed by ideally an IV infusion, or if this is not possible by regular intramuscular (IM) injections as follows: INTRAVENOUS MAINTENANCE REGIMEN: _The loading dose _is followed by an intravenous inf Pročitajte cijeli dokument